Irinotecan liposome plus anlotinib for SCLC after first chemo
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This trial tests a combination of two drugs—irinotecan liposome (a chemotherapy) and anlotinib (a targeted therapy)—as a second treatment for small cell lung cancer that returned quickly after initial chemo. The goal is to see if this combo can work better than standard options.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 to 75 years old.
- You have small cell lung cancer that came back or got worse within 6 months after your first platinum-based chemo.
- You have at least one tumor that can be measured on a scan.
- You are physically active enough to do daily activities (ECOG score 0-2).
- Your blood counts, liver, and kidney function are within acceptable ranges.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of three drugs (adebrelimab, irinotecan liposome, and famitinib) for people with extensive-stage small cell lung cancer whose disease got worse after initial immunotherapy. The goal is to see if this new combination can help control the cancer.
This trial tests a combination of a targeted chemotherapy bead injection into lung arteries, an oral anti-cancer drug, and an immunotherapy for advanced non-small cell lung cancer that has not responded to two prior treatments. It aims to see if this triple approach can help patients who have limited options left.
This trial tests a combination of two drugs (irinotecan liposome and ivonescimab) for people with advanced small cell lung cancer whose first treatment (chemotherapy with or without immunotherapy) stopped working. The goal is to see if this new combination can shrink tumors or slow the cancer's growth.
This trial tests a combination of a liposome-encased chemotherapy (irinotecan), a platinum drug, an immunotherapy, and a targeted therapy (anlotinib) as a maintenance treatment for extensive small cell lung cancer. The goal is to see if this approach helps keep the cancer from growing after initial successful treatment.
This trial tests a new combination of drugs (liposomal irinotecan plus others) as a first treatment for people with extensive-stage small cell lung cancer. It may offer a new approach if you haven't had any therapy yet.
This trial tests a combination of two drugs—lomustine (a chemotherapy) and anlotinib (a targeted therapy)—in patients whose small cell lung cancer has stopped responding to at least two previous treatment regimens. The goal is to see if this combination can slow or stop the cancer's growth.
Hear when a new Small Cell Lung Cancer Recurrent trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.